Revista de Hematología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista de Hematología >Year 2013, Issue 1

Crespo-Solís E, Rosas-López A, Vera-Zertuche M
Induction remission chemotherapy 7+3+7E or intermediate-dose cytarabine in adult patients with acute myeloid leukemia: a preliminar report
Rev Hematol Mex 2013; 14 (1)

Language: Español
References: 12
Page: 15-20
PDF: 605.19 Kb.

Full text


Background: On previous reports we have informed complete remission (CR) rates in patients with acute myeloid leukemia (AML) treated with chemotherapy 7+3 similar to those reported in the literature. Although incidence of early death during post-chemotherapy bone marrow aplasia is also similar to those reported by other groups, the CR rate after only one 7+3 cycle is considered suboptimal. This could be related to weak chemotherapy regimens or to a biologically more aggressive disease in our patients. Since 2010 we implemented more aggressive chemotherapy regimens in younger patients with AML (≤ 55 years) in order to improve the CR rate.
Methods: In this retrospective study we evaluated a series of adult patients with AML treated at our center between November 2010 and June 2012. The induction regimens used were 7+3+7E which consists of cytarabine given at 100 mg/m2/day, on days 1-7 and daunorubicin given at 45 mg/m2 on days 1-2, plus etoposide 75 mg/m2/day, on days 1-7 of cycle 1; or intermediate-dose cytarabine which consists of cytarabine given at 3 gr/m2/day, on days 1-3 plus daunorubicin given at 45 mg/m2/day, on days 2 and 3 of cycle 1. The goal of this preliminary report was to describe the CR rate and toxicity of the 7+3+7E and intermediate dose cytarabine during induction.
Results: We reported a total of 15 patients, median age of 40 years (range, 19 to 55 years). Analyzable metaphases were obtained in 73.3% (11/15) of the cases, 27.2% (3/11) were classified as having unfavorable cytogenetis, 54.5% (6/11) intermediate and 18.1% (2/11) favorable. Performance status was assessed by the ECOG scoring system, 80% of the patients were classified as ECOG 0-2 and the remaining 20% as ECOG 3-4. Comorbidities were detected in 40% of patients. Primary resistance was found in 6.6% of the patient population. The complete remission rate after the cycle 1 was 66.7%, with an early mortality rate of 13.3%, severe febrile neutropenia was observed in 100% of the patients and septic shock during induction in 6.7%. These results suggest that the use of more intensive induction regimens in younger patients with AML offers higher CR rates compared to our historical cohort of AML patients receiving 7+3 chemotherapy; with acceptable rates of septic shock and early mortality.

Key words: Induction to remission, citarabine, adult patients, and acute myeloid leukemia.


  1. Stone R. Acute myeloid leukemia. Hematology 2004;98-117.

  2. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, et al. Cytogenetic pattern in acute myeloid leukemia: a major reproducible determinant of outcome. Leukemia 1988;2:403-412.

  3. Infante-Sierra, Crespo-Solis E, López-Karpovitch X, Serralde A. López-de la Cruz I, Aguayo A. Reporte preliminar: Evaluación del esquema 7+3 en leucemia mieloide aguda y tasa de mortalidad temprana en una cohorte retrospectiva versus cohorte prospectiva. Rev Fac Med UNAM 2008;51:150-155.

  4. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo A, López-Karpovitch X, Crespo-Solís E. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008. Rev Invest Clin 2010;62:100.

  5. Othake S, Miyawaki S, Hiroyuki T, Kiyoi H, Shinagawa K, et al. Randomized study of induction therapy comparing standarddose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011;117:2358-2365.

  6. Lichtman MA, Liesveld JN. In: Acute Myelogenous Leukemia. Chapter 92. Williams Hematology. 6th ed. Editors: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligson U. p 1047. 2001.

  7. Arber DA, Brunning RD, Le Beau MM, Falini B. In: Acute Myeloid Leukemia and Related Precursor Neoplasms. Chapter 6. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Editors: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 4th ed. 2008;110.

  8. Cheson BD, Cassilth PA, Head DR, Schiffer, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-19.

  9. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.

  10. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, et al A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481-448.

  11. Ravandi F, Cortes J, Faderl S, O´Brien S, Gracía-Manero G, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818-5823.

  12. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027.

>Journals >Revista de Hematología >Year 2013, Issue 1

· Journal Index 
· Links 

Copyright 2019